Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer

When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with collaborators at Georgetown University, has preclinical data suggesting the drug may boost the benefits of immunotherapy in this tough-to-treat cancer.